The Manufacturers Life Insurance Company Trims Position in Prestige Consumer Healthcare Inc. $PBH

The Manufacturers Life Insurance Company decreased its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 10.0% during the first quarter, Holdings Channel reports. The fund owned 473,151 shares of the company’s stock after selling 52,430 shares during the period. The Manufacturers Life Insurance Company’s holdings in Prestige Consumer Healthcare were worth $28,044,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Norges Bank bought a new stake in shares of Prestige Consumer Healthcare during the 4th quarter valued at about $36,954,000. Brandes Investment Partners LP increased its position in shares of Prestige Consumer Healthcare by 93.2% during the 4th quarter. Brandes Investment Partners LP now owns 606,737 shares of the company’s stock valued at $37,430,000 after purchasing an additional 292,744 shares during the last quarter. Capital Research Global Investors lifted its stake in shares of Prestige Consumer Healthcare by 107.9% in the 4th quarter. Capital Research Global Investors now owns 561,497 shares of the company’s stock worth $34,639,000 after purchasing an additional 291,425 shares during the period. Squarepoint Ops LLC lifted its stake in shares of Prestige Consumer Healthcare by 316.1% in the 3rd quarter. Squarepoint Ops LLC now owns 301,866 shares of the company’s stock worth $18,836,000 after purchasing an additional 229,311 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Prestige Consumer Healthcare by 28.4% in the first quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock worth $46,997,000 after buying an additional 120,965 shares during the last quarter. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $50.29 on Friday. The company has a quick ratio of 2.25, a current ratio of 3.57 and a debt-to-equity ratio of 0.54. The business has a 50-day simple moving average of $48.30 and a two-hundred day simple moving average of $56.47. The stock has a market cap of $2.38 billion, a price-to-earnings ratio of 12.86, a PEG ratio of 1.61 and a beta of 0.35. Prestige Consumer Healthcare Inc. has a 52 week low of $42.62 and a 52 week high of $75.63.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Wednesday, May 13th. The company reported $1.23 EPS for the quarter, missing the consensus estimate of $1.39 by ($0.16). Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The company had revenue of $281.62 million during the quarter, compared to the consensus estimate of $293.64 million. During the same period last year, the business earned $1.32 EPS. The firm’s quarterly revenue was down 5.0% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. On average, analysts expect that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Canaccord Genuity Group cut their target price on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Oppenheimer cut shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Weiss Ratings downgraded shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, June 25th. Finally, Zacks Research cut shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Monday, May 18th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $70.75.

Insider Transactions at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 1,207 shares of the stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the sale, the vice president directly owned 42,820 shares of the company’s stock, valued at approximately $2,354,671.80. This represents a 2.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.50% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).